Item 5.07
Submission of Matters to a Vote of Security Holders.
Eagle Pharmaceuticals, Inc., or the Company, held its 2017 annual meeting of stockholders, or the Annual Meeting, on June 20, 2017, at which a quorum was present. At the Annual Meeting, the stockholders of the Company voted on the below proposals, each of which is described in more detail in the Companys definitive proxy statement on Schedule 14A, or the 2017 Proxy Statement, filed with the U.S. Securities and Exchange Commission on April 28, 2017. The following sets forth the certified voting results, including the number of votes cast for and against each matter, and if applicable, the number of abstentions and broker non-votes with respect to each matter.
(i)
The stockholders elected two directors to serve as members of the Companys board of directors until the 2020 annual meeting of stockholders. The stockholders present in person or by proxy cast the following numbers of votes in connection with the election of directors, resulting in the election of all director nominees:
Nominee
|
|
Votes For
|
|
Votes Withheld
|
|
Broker Non-Votes
|
|
Steven Ratoff
|
|
11,985,511
|
|
1,294,836
|
|
952,820
|
|
Douglas L. Braunstein
|
|
13,056,435
|
|
223,912
|
|
952,820
|
|
(ii)
The stockholders ratified the selection by the audit committee of the Companys board of directors of BDO USA, LLP as the independent registered public accounting firm of the Company for fiscal year 2017. There were 14,149,433 votes cast for the proposal; 47,119 votes cast against the proposal; 36,615 abstentions; and there were no broker non-votes.
(iii)
The stockholders approved, on an advisory basis, the compensation of the Companys named executive officers, as disclosed in the 2017 Proxy Statement. There were 8,355,389 votes cast for the proposal; 4,886,133 votes cast against the proposal; 38,825 abstentions; and there were 952,820 broker non-votes.
2